Get the Stockscreener App
1.74
2.35%
0.04
Calidi Biotherapeutics Inc stock is traded at $1.74, with a volume of 531.93K.
It is up +2.35% in the last 24 hours and down -79.17% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.70
Open:
$1.72
24h Volume:
531.93K
Relative Volume:
0.39
Market Cap:
$14.05M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-2.3616
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
-67.17%
1M Performance:
-79.17%
6M Performance:
-86.19%
1Y Performance:
-89.93%
1-Day Range:
$1.70
$1.8095
1-Week Range:
$1.61
$5.115
52-Week Range:
$1.61
$46.68
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.74 | 14.05M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi prices 1.47M units at $2.00 in underwritten public offering - MSN
Calidi Biotherapeutics Prices $6 Million Public Offering to Advance Targeted Cancer Therapies - citybuzz -
Technical Bounce Expected in Calidi Biotherapeutics Inc. Next Week2025 Trading Volume Trends & Short-Term High Return Ideas - newsyoung.net
Nasdaq Down 1%; Lowe's Posts Upbeat Earnings - Benzinga
Calidi Biotherapeutics Prices $6 Million Public Offering; Shares Fall - MarketScreener
Calidi Plunges 41%: A Capital Raise Gone Wrong? - AInvest
Calidi Biotherapeutics Plunges 40% on Capital Raise - AInvest
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewswire
$6M Capital Raise: Clinical-Stage Biotech Calidi Prices Offering With Strong Insider Support - Stock Titan
Why Did Calidi Biotherapeutics (CLDI) Plunge 15.33%? - AInvest
Can Calidi Biotherapeutics Inc. Escape Recent Bear ChannelJuly 2025 Drop Watch & Capital Efficient Trading Techniques - thegnnews.com
Heavy Losses Hit James Hardie, EnVVeno And Calidi Shares - Finimize
Calidi Plummets 21% on Reverse Split Jitters and Earnings Skepticism—What’s Next for the Biotech Play? - AInvest
Calidi Plummets 21% on Reverse Split Jitters and Earnings Concerns - AInvest
Has Calidi Biotherapeutics Inc. formed a bullish divergenceJuly 2025 Trade Ideas & Safe Entry Point Alerts - Newser
Published on: 2025-08-16 04:46:29 - Newser
How to forecast Calidi Biotherapeutics Inc. trends using time seriesOil Prices & Technical Confirmation Trade Alerts - Newser
Is a relief rally coming for Calidi Biotherapeutics Inc. holdersTreasury Yields & Stepwise Trade Signal Guides - Newser
Why Calidi Biotherapeutics Inc. stock attracts strong analyst attentionPortfolio Profit Report & Long-Term Growth Plans - Newser
Calidi Biotherapeutics Inc. stock momentum explainedJuly 2025 Recap & Community Verified Trade Signals - Newser
How to interpret RSI for Calidi Biotherapeutics Inc. stockEarnings Recap Report & Smart Money Movement Tracker - Newser
What’s next for Calidi Biotherapeutics Inc. stock pricePrice Action & Stepwise Entry and Exit Trade Signals - Newser
Calidi Biotherapeutics Announces Executive Departure Agreement - MSN
Calidi Biotherapeutics finalizes separation agreement with Dr. Boris Minev By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics finalizes separation agreement with Dr. Boris Minev - Investing.com India
Regression analysis insights on Calidi Biotherapeutics Inc. performanceJuly 2025 Closing Moves & Smart Swing Trading Alerts - Newser
Using Bollinger Bands to evaluate Calidi Biotherapeutics Inc.Risk Management & Consistent Profit Alerts - Newser
Calidi Biotherapeutics Reports Q2 2025 Financial Results and Advances in Oncology Therapies - citybuzz -
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - ADVFN Brasil
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pensacola News Journal
Is Calidi Biotherapeutics Inc. stock poised for growthFree Pattern Breakout Entry Stock Forecast - Newser
Calidi Biotherapeutics Q2 2025: Net Loss Narrowed to $5.7 Million, Cash Decreased to $5.3 Million. - AInvest
Calidi Biotherapeutics Secures FDA Fast Track Designation - TipRanks
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Bio Secures FDA Fast Track for Revolutionary Cancer Treatment as Q2 Shows Strong Pipeline Progress - Stock Titan
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split - TipRanks
Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Why LyondellBasell Industries Stock Slumped Today - The Globe and Mail
How does Calidi Biotherapeutics Inc. compare to its industry peersIdentify safe investments with exceptional yields - Jammu Links News
What is Calidi Biotherapeutics Inc. company’s growth strategyAchieve breakthrough gains with smart trades - Jammu Links News
Is it the right time to buy Calidi Biotherapeutics Inc. stockExtraordinary performance - Jammu Links News
1 Green Flag for Dutch Bros Stock Right Now - The Globe and Mail
Does Calidi Biotherapeutics Inc. stock perform well during market downturnsGet timely advice on market trends - Jammu Links News
Is Calidi Biotherapeutics Inc. a growth stock or a value stockAchieve consistent profits with smart trading - Jammu Links News
What are analysts’ price targets for Calidi Biotherapeutics Inc. in the next 12 monthsBuild a winning portfolio with smart picks - Jammu Links News
What makes Calidi Biotherapeutics Inc. stock price move sharplyDiscover high-impact stocks for growth - Jammu Links News
Is Calidi Biotherapeutics Inc. stock overvalued or undervaluedExceptional trading results - Jammu Links News
What are the technical indicators suggesting about Calidi Biotherapeutics Inc.Pre Market Entry Points To Watch Now - Jammu Links News
Chart based analysis of Calidi Biotherapeutics Inc. trendsChart Driven High Reward Trading Setup Presented - metal.it
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Cap:
|
Volume (24h):